iBET, Instituto de Biologia Experimental e Tecnológica, Apartado 12, Oeiras, 2781-901, Portugal.
ITQB-NOVA, Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Av. da República, Oeiras, 2780-157, Portugal.
Adv Sci (Weinh). 2022 May;9(15):e2104296. doi: 10.1002/advs.202104296. Epub 2022 Mar 24.
Extracellular vesicles (EV) are an attractive therapy to boost cardiac regeneration. Nevertheless, identification of native EV and corresponding cell platform(s) suitable for therapeutic application, is still a challenge. Here, EV are isolated from key stages of the human induced pluripotent stem cell-cardiomyocyte (hiPSC-CM) differentiation and maturation, i.e., from hiPSC (hiPSC-EV), cardiac progenitors, immature and mature cardiomyocytes, with the aim of identifying a promising cell biofactory for EV production, and pinpoint the genetic signatures of bioactive EV. EV secreted by hiPSC and cardiac derivatives show a typical size distribution profile and the expression of specific EV markers. Bioactivity assays show increased tube formation and migration in HUVEC treated with hiPSC-EV compared to EV from committed cell populations. hiPSC-EV also significantly increase cell cycle activity of hiPSC-CM. Global miRNA expression profiles, obtained by small RNA-seq analysis, corroborate an EV-miRNA pattern indicative of stem cell to cardiomyocyte specification, confirming that hiPSC-EV are enriched in pluripotency-associated miRNA with higher in vitro pro-angiogenic and pro-proliferative properties. In particular, a stemness maintenance miRNA cluster upregulated in hiPSC-EV targets the PTEN/PI3K/AKT pathway, involved in cell proliferation and survival. Overall, the findings validate hiPSC as cell biofactories for EV production for cardiac regenerative applications.
细胞外囊泡 (EV) 是一种很有吸引力的治疗方法,可以促进心脏再生。然而,鉴定天然 EV 及其适合治疗应用的相应细胞平台仍然是一个挑战。在这里,我们从人类诱导多能干细胞-心肌细胞 (hiPSC-CM) 分化和成熟的关键阶段分离 EV,即从 hiPSC (hiPSC-EV)、心脏祖细胞、未成熟和成熟的心肌细胞中分离 EV,目的是确定一个有前途的 EV 生产细胞工厂,并确定生物活性 EV 的遗传特征。hiPSC 和心脏衍生物分泌的 EV 显示出典型的大小分布特征和特定的 EV 标志物表达。生物活性测定显示,与来自定向细胞群的 EV 相比,用 hiPSC-EV 处理的 HUVEC 形成管和迁移的能力增加。hiPSC-EV 还显著增加 hiPSC-CM 的细胞周期活性。通过小 RNA-seq 分析获得的全球 miRNA 表达谱证实了 EV-miRNA 模式表明干细胞向心肌细胞特化,这证实了 hiPSC-EV 富含与体外更强的促血管生成和促增殖特性相关的多能性相关 miRNA。特别是,在 hiPSC-EV 中上调的一个维持干细胞特性的 miRNA 簇靶向参与细胞增殖和存活的 PTEN/PI3K/AKT 途径。总的来说,这些发现验证了 hiPSC 作为 EV 生产的细胞工厂,用于心脏再生应用。